Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average rating of “Hold” from the nineteen analysts that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $127.9412.

Several brokerages recently issued reports on ILMN. Barclays raised their target price on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Canaccord Genuity Group lifted their price objective on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Evercore set a $150.00 price objective on Illumina in a report on Friday, February 6th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Finally, Wall Street Zen upgraded Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 14th.

Illumina Stock Up 2.4%

Illumina stock opened at $120.54 on Tuesday. The business’s 50-day simple moving average is $135.52 and its two-hundred day simple moving average is $117.54. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market cap of $18.43 billion, a PE ratio of 22.12, a PEG ratio of 2.25 and a beta of 1.45. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.During the same period last year, the business posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts anticipate that Illumina will post 4.51 EPS for the current year.

Insider Activity at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.17% of the stock is owned by insiders.

Hedge Funds Weigh In On Illumina

Large investors have recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB grew its holdings in Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after purchasing an additional 79 shares during the period. HighPoint Advisor Group LLC grew its stake in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares during the period. Toronto Dominion Bank grew its stake in Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after acquiring an additional 92 shares during the period. Assetmark Inc. increased its holdings in Illumina by 10.2% in the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its position in Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 96 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.